## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.9% below STRENGTH zone (4.0-10.0%); PEG 2.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($537.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. 13,224 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Shorepoint Capital Partners LLC**
- Source: MarketBeat | 20251216T123059 | Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC initiated a new position in Thermo Fisher Scientific Inc. ($TMO), purchasing 13,224 shares valued at approximately $6.41 million in Q3, making it their 28th-largest holding. The company reported strong Q3 earnings, beating analyst estimates for EPS and revenue, and announced a $5.00 billion share buyback program and a quarterly dividend of $0.43 per share. Despite significant insider selling over the past three months, institutional ownership of TMO remains high, and analysts maintain a "Moderate Buy" consensus rating for the stock.

**2. Thermo Fisher Scientific (TMO) Stock: Latest Price, Todayâ€™s Institutional Moves, and Wall Street Forecasts on Dec. 17, 2025**
- Source: ts2.tech | 20251217T201427 | Somewhat-Bullish | Relevance: 100%
- This article provides a comprehensive overview of Thermo Fisher Scientific (TMO) stock on December 17, 2025, detailing its current price, significant institutional buying and selling, and Wall Street analyst forecasts. It highlights the company's strong position in the life sciences sector, recent M&A activities, and capital return programs, while also noting key risks and upcoming earnings dates.

**3. Mirador Capital Partners LP Buys 2,253 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251217T124925 | Bullish | Relevance: 100%
- Mirador Capital Partners LP increased its stake in Thermo Fisher Scientific Inc. by 25.1% in Q3, acquiring an additional 2,253 shares, bringing their total to 11,240 shares valued at approximately $5.45 million. The article details other institutional investments, recent analyst upgrades resulting in a "Moderate Buy" consensus, and notes a $5.0 billion stock buyback authorization alongside significant insider selling activity.

**4. Quintet Private Bank Europe S.A. Reduces Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251217T123825 | Somewhat-Bullish | Relevance: 100%
- Quintet Private Bank Europe S.A. has reduced its stake in Thermo Fisher Scientific Inc. by 7.7% in Q3, now holding 66,973 shares valued at $32.48 million, making it their 14th largest holding. This comes as Thermo Fisher reported strong Q3 earnings, issued positive FY2025 guidance, and announced a $5.0 billion stock buyback, despite insider selling activity. Analysts generally maintain a "Moderate Buy" rating with an average target price of $616.60 for the company.

**5. Assenagon Asset Management S.A. Buys 573,743 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251217T090913 | Bullish | Relevance: 100%
- Assenagon Asset Management S.A. significantly increased its stake in Thermo Fisher Scientific Inc. by buying an additional 573,743 shares, bringing its total holdings to 615,335 shares worth approximately $298.45 million. This move comes as Thermo Fisher Scientific reported strong quarterly earnings, exceeding analyst expectations, and announced a $5.00 billion stock buyback program along with a quarterly dividend. The company maintains a "Moderate Buy" rating from analysts, with an average price target of $616.60.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 22.8x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $211.3B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 22.8 |
| Current P/E | 24.7 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.9% (minimal 5-day change). Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-2.96), momentum weakening. RSI neutral at 43. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.93% (CS: 22) | Neutral |
| RSI_14 | 43.2 | Neutral |
| MACD Histogram | -2.96 | Bearish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.164x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $562.08
- **Stop Loss:** $537.40 (4.4% risk)
- **Target:** $586.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $21,359.04
- **Portfolio %:** 21.36%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*